UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 375

Sortiert nach

Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation

Cancer cell, 2015-11, Vol.28 (5), p.557-568

2015

Volltextzugriff (PDF)

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Journal of clinical oncology, 2012-01, Vol.30 (2), p.134-141

2012

Volltextzugriff (PDF)

Replication Stress and Chromatin Context Link ATM Activation to a Role in DNA Replication

Molecular cell, 2013-12, Vol.52 (5), p.758-766

2013

Volltextzugriff (PDF)

Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy

The Journal of clinical investigation, 2020-01, Vol.130 (1), p.258-271

2020

Volltextzugriff (PDF)

Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer

BMC cancer, 2019-01, Vol.19 (1), p.102-14, Article 102

2019

Volltextzugriff (PDF)

Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality

International journal of radiation oncology, biology, physics, 2016-06, Vol.95 (2), p.772-781

2016

Volltextzugriff (PDF)

The cell-line-derived subcutaneous tumor model in preclinical cancer research

Nature protocols, 2022-09, Vol.17 (9), p.2108-2128

2022

Volltextzugriff (PDF)

Cardio-Respiratory synchronized bSSFP MRI for high throughput in vivo lung tumour quantification

PloS one, 2019-02, Vol.14 (2), p.e0212172

2019

Volltextzugriff (PDF)

Shock subtypes by left ventricular ejection fraction following out-of-hospital cardiac arrest

Critical care (London, England), 2018-06, Vol.22 (1), p.162-162, Article 162

2018

Volltextzugriff (PDF)

Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2010-01, Vol.28 (2), p.193-201

2010

Volltextzugriff (PDF)

Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium

Pulmonary therapy, 2020-06, Vol.6 (1), p.9-22

2020

Volltextzugriff (PDF)

Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus

Molecular therapy, 2021-05, Vol.29 (5), p.1668-1682

2021

Volltextzugriff (PDF)

Orthotopic and metastatic tumour models in preclinical cancer research

Pharmacology & therapeutics (Oxford), 2024-05, Vol.257, p.108631-108631, Article 108631

2024

Volltextzugriff (PDF)

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer

Clinical cancer research, 2009-05, Vol.15 (10), p.3600-3609

2009

Volltextzugriff (PDF)

Short-Course Treatment With Gefitinib Enhances Curative Potential of Radiation Therapy in a Mouse Model of Human Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-03, Vol.88 (4), p.947-954

2014

Volltextzugriff (PDF)

Identification of anticancer drugs to radiosensitise BRAF -wild-type and mutant colorectal cancer

Cancer biology & medicine, 2019-05, Vol.16 (2), p.234-246

2019

Volltextzugriff (PDF)

The lifesaving effects of cardiac adhesions

Radiology case reports, 2023-07, Vol.18 (7), p.2461-2464

2023

Volltextzugriff (PDF)

DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models

Molecular cancer therapeutics, 2021-09, Vol.20 (9), p.1663-1671

2021

Volltextzugriff (PDF)

iRhom2 regulates ERBB signalling to promote KRAS-driven tumour growth of lung cancer cells

Journal of cell science, 2022-09, Vol.135 (17)

2022

Volltextzugriff (PDF)

The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells

Endocrine-related cancer, 2011-02, Vol.18 (1), p.1-11

2011

Volltextzugriff (PDF)

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Clinical and translational radiation oncology, 2020-11, Vol.25, p.61-66

2020

Volltextzugriff (PDF)

Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade

Molecular cancer therapeutics, 2007-02, Vol.6 (2), p.471-483

2007

Volltextzugriff (PDF)

Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126

Clinical cancer research, 2004-06, Vol.10 (11), p.3650-3657

2004

Volltextzugriff (PDF)

The Effects of Vandetanib on Paclitaxel Tumor Distribution and Antitumor Activity in a Xenograft Model of Human Ovarian Carcinoma

Neoplasia (New York, N.Y.), 2009-11, Vol.11 (11), p.1155,IN7-1164,IN7

2009

Volltextzugriff (PDF)

Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models

Clinical cancer research, 2002-06, Vol.8 (6), p.1974-1983

2002

Volltextzugriff (PDF)

1 – 25 von 375

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(336)
Mit Volltextzugriff
(342)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(375)
Japanisch
(40)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Replication Stress and Chromatin Context Link ATM Activation to a Role in DNA Replication

Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy

Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer

Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality

The cell-line-derived subcutaneous tumor model in preclinical cancer research

Cardio-Respiratory synchronized bSSFP MRI for high throughput in vivo lung tumour quantification

Shock subtypes by left ventricular ejection fraction following out-of-hospital cardiac arrest

Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer

Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium

Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus

Orthotopic and metastatic tumour models in preclinical cancer research

Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer

Short-Course Treatment With Gefitinib Enhances Curative Potential of Radiation Therapy in a Mouse Model of Human Non-Small Cell Lung Cancer

Identification of anticancer drugs to radiosensitise BRAF -wild-type and mutant colorectal cancer

The lifesaving effects of cardiac adhesions

DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models

iRhom2 regulates ERBB signalling to promote KRAS-driven tumour growth of lung cancer cells

The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade

Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126

The Effects of Vandetanib on Paclitaxel Tumor Distribution and Antitumor Activity in a Xenograft Model of Human Ovarian Carcinoma

Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models

Suchergebnisse filtern